Rezolute, Inc. (NASDAQ:RZLT) Given Average Rating of “Buy” by Analysts

Shares of Rezolute, Inc. (NASDAQ:RZLT) have received an average rating of “Buy” from the eight analysts that are currently covering the stock, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $24.38.

RZLT has been the topic of a number of analyst reports. Craig Hallum upgraded shares of Rezolute to a “strong-buy” rating in a research note on Tuesday, February 4th. Wedbush reissued an “outperform” rating and issued a $112.00 price objective on shares of Rezolute in a research note on Monday, November 4th. HC Wainwright restated a “buy” rating and set a $14.00 price objective on shares of Rezolute in a research report on Thursday. Guggenheim reaffirmed a “buy” rating on shares of Rezolute in a report on Monday, February 10th. Finally, JMP Securities boosted their price target on Rezolute from $8.00 to $9.00 and gave the stock a “market outperform” rating in a report on Thursday.

Insider Transactions at Rezolute

In other Rezolute news, CFO Daron Evans acquired 10,000 shares of Rezolute stock in a transaction on Wednesday, December 18th. The stock was purchased at an average price of $4.29 per share, for a total transaction of $42,900.00. Following the purchase, the chief financial officer now directly owns 150,900 shares of the company’s stock, valued at $647,361. This trade represents a 7.10 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 18.39% of the company’s stock.

Institutional Trading of Rezolute

Large investors have recently bought and sold shares of the company. Geode Capital Management LLC lifted its holdings in Rezolute by 39.0% during the third quarter. Geode Capital Management LLC now owns 491,601 shares of the company’s stock valued at $2,385,000 after purchasing an additional 137,905 shares during the last quarter. MML Investors Services LLC purchased a new position in shares of Rezolute in the third quarter worth about $57,000. JPMorgan Chase & Co. bought a new stake in shares of Rezolute in the third quarter valued at approximately $42,000. State Street Corp lifted its stake in shares of Rezolute by 11.6% during the 3rd quarter. State Street Corp now owns 125,472 shares of the company’s stock valued at $609,000 after buying an additional 13,000 shares in the last quarter. Finally, Cubist Systematic Strategies LLC boosted its holdings in Rezolute by 366.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 54,237 shares of the company’s stock worth $233,000 after buying an additional 42,597 shares during the period. 82.97% of the stock is owned by hedge funds and other institutional investors.

Rezolute Stock Performance

RZLT opened at $4.61 on Friday. The stock has a fifty day moving average of $4.86 and a 200-day moving average of $4.90. Rezolute has a fifty-two week low of $1.13 and a fifty-two week high of $6.19. The company has a market capitalization of $279.07 million, a P/E ratio of -3.63 and a beta of 1.10.

Rezolute (NASDAQ:RZLT) last announced its earnings results on Wednesday, February 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.11. On average, equities research analysts predict that Rezolute will post -0.99 earnings per share for the current fiscal year.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.